Skip to main content
NCBI home page
Immunology logoLink to Immunology
. 1994 Apr;81(4):546–550.

Effect of serine/threonine kinase inhibitors on motility of human lymphocytes and U937 cells.

K M Thorp 1, C Southern 1, N Matthews 1
PMCID: PMC1422375  PMID: 8039806

Abstract

Mononuclear cell migration across the endothelium and through connective tissue into inflammatory sites is a multi-step process. After adhesion to the endothelium, there is an initial change in shape from spherical to irregular, followed by the migratory phase itself in which the cells constantly change in shape. In this paper we have investigated the possibility that the shape-changing in this latter phase is controlled by serine/threonine phosphorylation. For this purpose, we used a spontaneously shape-changing variant of U937 monocytoid cells as well as human peripheral blood lymphocytes that had been previously activated by anti-CD3. To test the role of phosphorylation in shape-changing, a wide range of serine/threonine kinase inhibitors was tested, including ML-7, KT5720, KT823, H7, H8, staurosporine, calphostin C, sphingosine, bisindolylmaleimide, chelerythrine and KN-62. Only those compounds which inhibited protein kinase C prevented lymphocyte and U937 shape-change and transmigration across polycarbonate filters. However, one specific protein kinase C inhibitor, bisindolylmaleimide, stimulated lymphocyte shape-change. In conclusion, these studies show that activation of a serine/threonine kinase is necessary for the constant shape-changing required for motility of mononuclear cells. The kinase may be a protein kinase C isotype or a closely related enzyme.

Full text

PDF
546

Images in this article

548Figure 1
on p.548

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ager A., Mistry S. Interaction between lymphocytes and cultured high endothelial cells: an in vitro model of lymphocyte migration across high endothelial venule endothelium. Eur J Immunol. 1988 Aug;18(8):1265–1274. doi: 10.1002/eji.1830180818. [DOI] [PubMed] [Google Scholar]
  2. Arencibia I., Pedari L., Sundqvist K. G. Induction of motility and alteration of surface membrane polypeptides in lymphocytes by contact with autologous and allogeneic fibroblasts. Exp Cell Res. 1987 Sep;172(1):124–133. doi: 10.1016/0014-4827(87)90099-1. [DOI] [PubMed] [Google Scholar]
  3. Harris H. The stimulation of lymphocyte motility by cultured high endothelial cells and its inhibition by pertussis toxin. Int Immunol. 1991 Jun;3(6):535–542. doi: 10.1093/intimm/3.6.535. [DOI] [PubMed] [Google Scholar]
  4. Hartwig J. H., Thelen M., Rosen A., Janmey P. A., Nairn A. C., Aderem A. MARCKS is an actin filament crosslinking protein regulated by protein kinase C and calcium-calmodulin. Nature. 1992 Apr 16;356(6370):618–622. doi: 10.1038/356618a0. [DOI] [PubMed] [Google Scholar]
  5. Haston W. S., Shields J. M. Contraction waves in lymphocyte locomotion. J Cell Sci. 1984 Jun;68:227–241. doi: 10.1242/jcs.68.1.227. [DOI] [PubMed] [Google Scholar]
  6. Haston W. S., Shields J. M., Wilkinson P. C. Lymphocyte locomotion and attachment on two-dimensional surfaces and in three-dimensional matrices. J Cell Biol. 1982 Mar;92(3):747–752. doi: 10.1083/jcb.92.3.747. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Herbert J. M., Augereau J. M., Gleye J., Maffrand J. P. Chelerythrine is a potent and specific inhibitor of protein kinase C. Biochem Biophys Res Commun. 1990 Nov 15;172(3):993–999. doi: 10.1016/0006-291x(90)91544-3. [DOI] [PubMed] [Google Scholar]
  8. Jordan M. L., Wright J. Evidence that protein kinase C regulates allosensitized T lymphocyte function. J Surg Res. 1991 Jun;50(6):569–573. doi: 10.1016/0022-4804(91)90043-l. [DOI] [PubMed] [Google Scholar]
  9. Kimura S., Kawa S., Ruan F., Nisar M., Sadahira Y., Hakomori S., Igarashi Y. Effect of sphingosine and its N-methyl derivatives on oxidative burst, phagokinetic activity, and trans-endothelial migration of human neutrophils. Biochem Pharmacol. 1992 Oct 20;44(8):1585–1595. doi: 10.1016/0006-2952(92)90476-y. [DOI] [PubMed] [Google Scholar]
  10. Ko F. N., Chen I. S., Wu S. J., Lee L. G., Haung T. F., Teng C. M. Antiplatelet effects of chelerythrine chloride isolated from Zanthoxylum simulans. Biochim Biophys Acta. 1990 May 22;1052(3):360–365. doi: 10.1016/0167-4889(90)90144-3. [DOI] [PubMed] [Google Scholar]
  11. Koizumi T., Nakao Y., Matsui T., Katakami Y., Katakami N., Fujita T. Inhibitors of IL-2 production and IL-2 receptor expression in human leukemic T-cell line, Jurkat. Cell Immunol. 1986 Dec;103(2):469–475. doi: 10.1016/0008-8749(86)90107-3. [DOI] [PubMed] [Google Scholar]
  12. Martiny-Baron G., Kazanietz M. G., Mischak H., Blumberg P. M., Kochs G., Hug H., Marmé D., Schächtele C. Selective inhibition of protein kinase C isozymes by the indolocarbazole Gö 6976. J Biol Chem. 1993 May 5;268(13):9194–9197. [PubMed] [Google Scholar]
  13. Nakao Y., Matsuda S., Matsui T., Koizumi T., Katakami Y., Fujita T., Ito Y. Inhibitors of 12-O-tetradecanoylphorbol-13-acetate (TPA)-induced multinucleated cell formation and HTLV-I p19 antigen expression in HTLV-I-infected T-cell line KH-2Lo. Int J Cancer. 1986 Jun 15;37(6):911–917. doi: 10.1002/ijc.2910370618. [DOI] [PubMed] [Google Scholar]
  14. Saitoh M., Ishikawa T., Matsushima S., Naka M., Hidaka H. Selective inhibition of catalytic activity of smooth muscle myosin light chain kinase. J Biol Chem. 1987 Jun 5;262(16):7796–7801. [PubMed] [Google Scholar]
  15. Shimizu Y., Newman W., Tanaka Y., Shaw S. Lymphocyte interactions with endothelial cells. Immunol Today. 1992 Mar;13(3):106–112. doi: 10.1016/0167-5699(92)90151-V. [DOI] [PubMed] [Google Scholar]
  16. Sozzani S., Luini W., Molino M., Jílek P., Bottazzi B., Cerletti C., Matsushima K., Mantovani A. The signal transduction pathway involved in the migration induced by a monocyte chemotactic cytokine. J Immunol. 1991 Oct 1;147(7):2215–2221. [PubMed] [Google Scholar]
  17. Stossel T. P. From signal to pseudopod. How cells control cytoplasmic actin assembly. J Biol Chem. 1989 Nov 5;264(31):18261–18264. [PubMed] [Google Scholar]
  18. Tamaoki T., Nomoto H., Takahashi I., Kato Y., Morimoto M., Tomita F. Staurosporine, a potent inhibitor of phospholipid/Ca++dependent protein kinase. Biochem Biophys Res Commun. 1986 Mar 13;135(2):397–402. doi: 10.1016/0006-291x(86)90008-2. [DOI] [PubMed] [Google Scholar]
  19. Tokumitsu H., Chijiwa T., Hagiwara M., Mizutani A., Terasawa M., Hidaka H. KN-62, 1-[N,O-bis(5-isoquinolinesulfonyl)-N-methyl-L-tyrosyl]-4-phenylpiperazi ne, a specific inhibitor of Ca2+/calmodulin-dependent protein kinase II. J Biol Chem. 1990 Mar 15;265(8):4315–4320. [PubMed] [Google Scholar]
  20. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., Loriolle F. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J Biol Chem. 1991 Aug 25;266(24):15771–15781. [PubMed] [Google Scholar]
  21. Verschueren H., De Baetselier P., Bereiter-Hahn J. Dynamic morphology of metastatic mouse T-lymphoma cells invading through monolayers of 10T1/2 cells. Cell Motil Cytoskeleton. 1991;20(3):203–214. doi: 10.1002/cm.970200304. [DOI] [PubMed] [Google Scholar]
  22. Verschueren H., Dekegel D., De Baetselier P. Difference in motile behavior between lymphoma variants with different invasive and metastatic capabilities. Invasion Metastasis. 1988;8(1):31–44. [PubMed] [Google Scholar]
  23. Wilkinson P. C. The locomotor capacity of human lymphocytes and its enhancement by cell growth. Immunology. 1986 Feb;57(2):281–289. [PMC free article] [PubMed] [Google Scholar]
  24. Zimmermann A., Keller H. Effects of staurosporine, K 252a and other structurally related protein kinase inhibitors on shape and locomotion of Walker carcinosarcoma cells. Br J Cancer. 1992 Dec;66(6):1077–1082. doi: 10.1038/bjc.1992.413. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Zimmermann A., Keller H. Shape changes and chemokinesis of Walker carcinosarcoma cells: effects of protein kinase inhibitors (HA-1004, polymyxin B, sangivamycin and tamoxifen) and an inhibitor of diacylglycerol kinase (R 59022). Anticancer Res. 1993 Mar-Apr;13(2):347–354. [PubMed] [Google Scholar]

Articles from Immunology are provided here courtesy of British Society for Immunology

RESOURCES